{
  "symbol": "ICUI",
  "company": "ICU Medical, Inc.",
  "generated_at": "2026-06-24T07:36:48.724Z",
  "event_count": 3,
  "events": [
    {
      "type": "pipeline_event",
      "ts": "2026-05-14T01:25:08.543Z",
      "stage": "analyst",
      "outcome": "skip",
      "reason": "Score of 29/100 reflects a complete absence of insider buying, elevated leverage (~3.4x net debt/EBITDA), and an unresolved FDA warning letter that outweigh the modest valuation discount. Anti-signal flags for dilution and concentration, combined with a score well below the skip threshold, justify passing on this dossier.",
      "trigger": "[insider_cluster_universe] 3 Form 4 filings in last 14 days · at least one open-market P/S trade verified",
      "source": "idle_hunter"
    },
    {
      "type": "analyst_decision",
      "ts": "2026-05-14T01:25:08.524Z",
      "skip": true,
      "reason": "Score of 29/100 reflects a complete absence of insider buying, elevated leverage (~3.4x net debt/EBITDA), and an unresolved FDA warning letter that outweigh the modest valuation discount. Anti-signal flags for dilution and concentration, combined with a score well below the skip threshold, justify passing on this dossier.",
      "score": 29,
      "breakdown": {
        "smart_money": 0,
        "options_flow": 6,
        "catalyst": 20,
        "mispricing": 0,
        "quality": 0,
        "technical": 3
      },
      "debug_path": "drafts/2026-05-14-ICUI.analyst.debug.json"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-05-14T01:24:22.621Z",
      "summary": "ICU Medical is a pure-play infusion therapy and vascular access medical device company that has undergone significant structural transformation — the divestiture of the IV Solutions business to an Otsuka JV in May 2025 explains most of the reported -12% revenue decline. Forward P/E of ~13x with analyst targets near $174 represents meaningful upside, but no true open-market insider purchases were found: the recent Form 4 cluster consists entirely of RSU vesting with simultaneous tax-withholding sales (F-codes) and option exercises converted at market prices. No director or executive bought ICUI on the open market in the past 90 days. The stock is near its 52-week low, below both moving averages but has a recent MACD bullish cross, giving it income/strangle potential rather than an asymmetric long setup.",
      "verdict": "range_bound_or_income",
      "confidence": 4,
      "tool_calls": 24,
      "walltime_min": 21,
      "debug_path": "dossiers/2026-05-14-ICUI.scout.debug.json"
    }
  ],
  "lessons": [],
  "chart_signal": {
    "ticker": "ICUI",
    "call": "HOLD",
    "confidence": 2,
    "score": 1,
    "factors": {
      "above_200dma": "+2",
      "above_50dma": "+1",
      "momentum_flat": "0 (0.3%)",
      "rsi_neutral": "0 (50.4)",
      "recent_macd_bearish_cross": "-2 (1d ago)",
      "from_high": "0 (-14.5%)"
    },
    "summary": "HOLD (score +1) · 12-1 mom 0.3% · RSI 50.4 · above_both · -14.5% from high",
    "last_close": 135.52,
    "one_month_ago_close": 131.31,
    "twelve_month_ago_close": 130.88,
    "twelve_one_momentum_pct": 0.33,
    "rsi_14": 50.4,
    "ma_stack": "above_both",
    "from_period_high_pct": -14.52,
    "period_high": 158.54,
    "price_targets": {
      "bear": 110.98,
      "fair": 145.88,
      "bull": 200,
      "bear_return_pct": -18.1,
      "fair_return_pct": 7.6,
      "bull_return_pct": 47.6,
      "method": "street_targets ⨯ chart_floors",
      "street": {
        "target_low": 160,
        "target_mean": 172.5,
        "target_high": 200,
        "analyst_count": 8
      }
    },
    "generated_at": "2026-06-24T07:36:48.721Z"
  }
}